| [1] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer guideline(2014.V3) [M]. Fort Washington: National Comprehensive Cancer Network,2014.
|
| [2] |
Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer(ABC 1) [J].Breast,2012,21(3):242-252.
|
| [3] |
Early Breast Cancer Trialist’s Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet,2005,365(9472):1687-1717.
|
| [4] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS,a randomised trial[J]. Lancet,2013,381(9869):805-816.
|
| [5] |
Gray RG, Rea D, Handley K, et al. aTTom:Long-term effects of continuing adjuvant tamoxifen to 10 years versus stoppong at 5 years in 6953 women with early breast cancer[EB/OL].[2014-01-04]. http:/ /meetinglibrary. asco. org/content/112995-132.
|
| [6] |
Yu KD,Wu J,Shen ZZ,et al. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy [J]. J Clin Endocrinol Metab,2012,97(12):E2201-2209.
|
| [7] |
He M, Tang LC, Yu KD,et al. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer[J]. Eur J Surg Oncol,2012,38(11):1022-1028.
|
| [8] |
Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer:NCIC CTG MA.27--a randomized controlled phase III trial[J].J Clin Oncol,2013,31(11):1398-1404.
|
| [9] |
Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptorrich stage 2 to 3 breast cancer:clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031[J]. J Clin Oncol,2011,29(17):2342-2349.
|
| [10] |
Regan MM, Price KN, Giobbie-Hurder A, et al. Interpreting Breast International Group (BIG) 1-98:a randomized,doubleblind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer [J]. Breast Cancer Res,2011,13(3):209.
|
| [11] |
Howell A, Cuzick J, Baum M, et al. Results of the ATAC(Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer[J]. Lancet,2005,365(9453):60-62.
|
| [12] |
van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial[J]. Lancet,2011,377 (9762):321-331.
|
| [13] |
Metzger O, Giobbie-Hurder A, Mallon E, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial[J]. Cancer Res,2012,72(24 Suppl 3):89.
|
| [14] |
张少华,江泽飞,宋三泰,等. 芳香化酶抑制剂不同顺序治疗转移性乳腺癌的临床研究[J]. 中国癌症杂志,2010,20(5):385-389.
|
| [15] |
Howell A,Robertson JF,Quaresma Albano J, et al. Fulvestrant,formerly ICI 182 780, is as effective as anastrozole in postmenopausal women with advnced breast cancer progressing after prior endocrine treatment[J]. J Clin Oncol,2002,20(16):3396-3403.
|
| [16] |
Osborne CK, Pippen J, Jones SE, et al. Double-blind,randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy:results of a North American trial[J]. J Clin Oncol,2002,20(16):3386-3395.
|
| [17] |
Xu B, Jiang Z, Shao Z, et al. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer:results of a multicentre, double-blind, randomised phase III trial[J]. Cancer Chemother Pharmacol,2011,67(1):223-230.
|
| [18] |
Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer:results from the FIRST study[J]. J Clin Oncol,2009,27(27):4530-4535.
|
| [19] |
Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an openlabel randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol,2012,30(16):1919-1925.
|
| [20] |
Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial[J]. Lancet Oncol,2013,14(10):989-998.
|
| [21] |
Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer [J]. N Engl J Med,2012,367(5):435-444.
|
| [22] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2010,28(30):4594-4600.
|
| [23] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med,2012,366(6):520-529.
|
| [24] |
Campone M, Bachelot T, Gnant M, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study[J]. Eur J Cancer,2013,49(12):2621-2632.
|
| [25] |
Massarweh S,Romond E,Black EP,et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure[J]. Breast Cancer Res Treat,2014,143(2):325-332.
|
| [26] |
Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study[J]. J Clin Oncol,2012,30(22):2718-2724.
|
| [27] |
Schwartz GK, Lorusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor,administered in 3-week cycles (Schedule 2/1) [J]. Br J Cancer,2011,104(12):1862-1868.
|
| [28] |
Paul D, Vukelja SJ, Holmes FA, et al. Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor therapy. The 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013 [ C]. San Antonio:SABCS,2013.
|
| [29] |
Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J]. J Clin Oncol,2013,31(2):195-202.
|